This review is of a recent meta-analysis of omalizumab treatment in adolescent and adult patients with chronic idiopathic urticaria.
This analysis is based on 67 separate observational studies and independent commentary is provided by Dr. Daman Langguth, a clinical immunologist at the Wesley hospital and Director of immunology at Sullivan Nicolaides Pathology.
Please login below to download this issue (PDF)